Welcome to our dedicated page for MetaVia SEC filings (Ticker: MTVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
MetaVia Inc. Chief Financial Officer Woodworth Marshall H received a grant of 28,000 shares of common stock on January 23, 2026, reported as an acquisition at a price of
The grant vests in two equal parts, with 50% vesting on each of the first and second anniversaries of the grant date, contingent on continued service. Following this award, the officer beneficially owns 30,734 shares directly, a figure that reflects MetaVia’s completed 1-for-11 reverse stock split on
MetaVia Inc. filed an 8-K to disclose final 2025 cash bonuses for its top executives and to update its “Summary Compensation Table for 2025 and 2024.” The Compensation Committee approved discretionary cash bonuses for the company’s principal executive officer and other named executive officers for the fiscal year ended December 31, 2025.
For 2025, President and Chief Executive Officer Hyung Heon Kim received salary of $479,723, a bonus of $239,862, and total compensation of $756,328. Chief Financial Officer Marshall H. Woodworth received salary of $393,300, a bonus of $157,320, and total compensation of $562,985. For 2025, “All Other Compensation” for the named executives was related to health and welfare benefits paid by MetaVia.
MetaVia Inc. insider activity: CEO and President Kim Hyung Heon, who also serves as a director of MetaVia Inc. (MTVA), received 32,000 shares of common stock on January 23, 2026 in a transaction coded "A" for acquisition at a price of $0 per share. The filing explains this represents a grant of restricted stock units under MetaVia's 2022 Amended and Restated Equity Incentive Plan, vesting 50% on each of the first and second anniversaries of the grant date, subject to continued service.
After this award, Kim Hyung Heon beneficially owns 37,545 shares of MetaVia common stock directly. The filing notes this ownership figure reflects MetaVia’s completed 1-for-11 reverse stock split on December 4, 2025.
MetaVia Inc. completed an underwritten public offering of Class A and Class B units, raising approximately $7.7 million in net proceeds. The company sold 1,006,870 Class A Units, each with one common share plus Series C and Series D common warrants, and 1,998,704 Class B Units, each with a pre-funded warrant plus additional Series C and Series D warrants. The Series C and Series D warrants are immediately exercisable at $3.10 per share, with the Series C warrants expiring five years after January 16, 2026 and the Series D warrants expiring two years after that date.
MetaVia plans to use the net proceeds for working capital and general corporate purposes, including continuing clinical development of its obesity candidate DA-1726. The underwriter received a 45-day over-allotment option for additional shares and warrants, which was fully exercised, and company executives and directors agreed to a 75-day lock-up on sales of company securities following the offering’s closing.
MetaVia Inc. is offering 614,840 Class A Units and 1,998,704 Class B Units, plus 9,839,336 shares of common stock issuable upon exercise of pre-funded and common warrants. Each Class A Unit includes one common share and 1.5 Series C and 1.5 Series D common warrants at a combined price of $3.10; each Class B Unit replaces the share with a pre-funded warrant at $3.099. Gross proceeds are expected to be about $8.10 million, with estimated net proceeds of approximately $6.6 million before any warrant exercises.
MetaVia plans to use the cash primarily for working capital and to continue developing DA-1726 for obesity. The company is a clinical-stage biotech also advancing Vanoglipel (DA-1241) for MASH and Type 2 diabetes and recently reported positive Phase 1 and Phase 2a topline data. MetaVia reports preliminary year-end 2025 cash of about $10.3 million with no debt and expects current resources plus this offering to fund operations into the third quarter of 2026, but it has a substantial accumulated deficit and a going concern warning.
MetaVia Inc. is registering up to 919,681 Class A Units or 919,681 Class B Units, plus up to 3,678,723 shares of common stock issuable upon exercise of pre-funded and common warrants, in a primary offering expected to raise about $6.0 million at an assumed $8.155 per unit.
The clinical-stage biotech develops cardiometabolic drugs, led by Vanoglipel (DA-1241) for MASH and Type 2 diabetes and DA-1726 for obesity. Recent Phase 1 multiple-ascending-dose data for DA-1726 showed up to 9.1% weight loss and meaningful waist, glucose and liver stiffness reductions over eight weeks in a 48 mg cohort, supporting further Phase 1 parts in 2026.
On a preliminary basis, MetaVia expects about $10.3 million in cash and cash equivalents and no debt as of December 31, 2025, but has an accumulated deficit of $146.9 million and a going concern warning. The company expects the offering proceeds plus existing cash to fund operations into the third quarter of 2026, mainly to advance DA-1726 and for working capital.
MetaVia Inc. (MTVA) reports that Nasdaq has granted the company a 180‑day extension, until May 26, 2026, to regain compliance with Nasdaq’s minimum bid price requirement, which calls for a closing bid of at least $1.00 per share for 10 consecutive business days. The extension follows an earlier notice that MetaVia’s stock had traded below $1.00 for 30 straight trading days.
MetaVia noted it had more than $5 million in stockholders’ equity as of September 30, 2025 and already has shareholder approval to implement a reverse stock split at a ratio between 1‑for‑5 and 1‑for‑30 at the board’s discretion. The company plans to monitor its share price and may use a reverse split to help restore compliance. If it does not regain compliance by the new deadline, its shares could be subject to delisting from Nasdaq, though the company would be able to appeal.
MetaVia Inc. (MTVA) reported positive Phase 2a results for vanoglipel (DA-1241), a GPR119 agonist being studied for MASH, with data presented at AASLD The Liver Meeting 2025 in Washington, D.C.
After 16 weeks, mean HbA1c decreased by −0.54%p with monotherapy and −0.66%p with combination therapy. From a baseline of 6.99%, patients recorded HbA1c reductions of 0.37%p, 0.41%p, and 0.54%p at weeks 4, 8, and 16 (p < 0.05 vs. placebo). Vanoglipel significantly lowered plasma ALT in participants with baseline ALT between 40–200 U/L, improved steatosis by CAP and liver stiffness by VCTE, and showed better FAST and NIS‑4 scores. Biomarkers of cell death (CK18F/M30), inflammation (hs‑CRP, CCL2), and fibrosis (TIMP1) declined, and 100 mg reduced pathogenic plasma lipids.
The treatment was well tolerated across all groups, with no treatment‑emergent adverse events leading to discontinuation reported for vanoglipel; one discontinuation occurred in the placebo group.
MetaVia Inc. launched an at-the-market offering of up to $2,300,000 of Common Stock, to be sold from time to time through Ladenburg Thalmann under a Sales Agreement as “at the market offerings” under Rule 415.
Ladenburg will act as sales agent or principal and receive a commission of up to 3.0% of the aggregate gross sales price. MetaVia intends to use any net proceeds for working capital and general corporate purposes. Under General Instruction I.B.6 of Form S-3, the company notes a public float of $2,329,870 and is limited to selling no more than one‑third of its public float in any 12‑month period while below $75 million.
Shares outstanding were 24,214,788 as of September 30, 2025. The company illustrates that, assuming sales of 2,300,000 shares at $1.00, shares outstanding could reach 26,514,788 and new investors would see illustrative dilution of $0.69 per share. The filing also highlights Nasdaq minimum bid price deficiency risk and prior stockholder approval for a potential reverse split.